Compare
Compare drugs side by side
Pick up to three. Green marks the best value in each row among the drugs shown.
| Tirzepatide Zepbound / Mounjaro | Semaglutide 2.4 mg Wegovy | Oral semaglutide 25 mg* Wegovy pill | |
|---|---|---|---|
| Stage | FDA approved | FDA approved | FDA approved |
| Company | Eli Lilly | Novo Nordisk | Novo Nordisk |
| Mechanism | GIP/GLP-1 dual agonist | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Dosing | Injection, weekly | Injection, weekly | Oral, daily |
| Main trial | SURMOUNT-1 (72 wk, Phase 3) | STEP 1 (68 wk, Phase 3) | OASIS 4 (64 wk, Phase 3) * Small trial: 307 people |
| Weight loss | 22.5% | 16.9% | 16.6% |
| Nausea | 31.0% | 44.2% | 46.6% |
| Vomiting | 12.2% | 24.8% | 30.9% |
| Diarrhea | 23.0% | 31.5% | 17.6% |
| Constipation | 11.7% | 23.4% | 20.1% |
| Quit due to side effects | 6.2% | 7.0% | 6.9% |
| Index score | 8.8 | 4.5 | 4.6 |
Results come from separate trials of different lengths and populations, not head-to-head comparisons.
* Wegovy pill: small trial with dose reductions. OASIS 4 included 307 adults, only about 205 of them on the pill, against 1,961 in STEP 1 for the injection, so its side-effect rates are less reliable. In addition, 18.6% of participants who completed treatment ended on a lower dose than 25 mg, which probably kept some from stopping and lowered the reported 6.9% discontinuation rate. Its ranking against the injection should be treated as provisional.